| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Wang,Jian-Zhi | Chairman | 5.69% | FENG SI INVESTMENT LTD. |
| Yan,Lin-Quan | Vice Chairman | 6.64% | FU KE SHEN INVESTMENT LTD. |
| Gan,Pei | Director | 1.82% | |
| Shi,Ge-Rui | Director | 0.00% | |
| Fang,Yan-Ling | Independent Director | 0.00% | |
| Zhang,Wen-Chang | Independent Director | 0.00% | |
| Wu,Li-Ren | Independent Director | 0.00% |
Change Company Name to Pharmosa Biopharm Inc.
2024/05/13
Change Company Name to GUOYI PHARMACEUTICAL TECHNOLOGY CO., LTD. (FORMER NAME: WANLING PHARMACEUTICAL TECHNOLOGY CO., LTD.)
2022/07/04
Change Person in Charge to Wang,Jian-Zhi
2021/10/29
Change Capital to 1,000,000,000
2021/09/08
Change Capital to 500,000,000
2019/07/22
Change Company Name to Pharmosa Biopharm Inc.
2016/10/27
Change Capital to 300,000,000
2014/01/02
Change Capital to 93,000,000
2012/12/28
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Operating income | 0 | 167,568 | 314,500 |
| Operating cost | 0 | 40,665 | - |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 0 | 126,903 | 314,500 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 0 | 126,903 | 314,500 |
| Operating expenses | 110,601 | 345,470 | 317,324 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -110,601 | -218,567 | -2,824 |
| Non-operating income and expenses | 17,678 | 51,914 | 11,280 |
| Net profit (loss) before tax | -92,923 | -166,653 | 8,456 |
| Income tax expense (benefits) | - | 0 | 0 |
| Net profit (loss) of ongoing business for the current period | -92,923 | -166,653 | 8,456 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -92,923 | -166,653 | 8,456 |
| Other comprehensive profit (loss), net | 2 | 11 | 1 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -92,921 | -166,642 | 8,457 |
| Net profit (loss) attributable to owners of parent company | -92,923 | -166,653 | 8,456 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | -92,921 | -166,642 | 8,457 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | 0 | -1 | 0 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | -93,314 | -127,164 | 42,421 |
| Net cash inflows (outflows) from investing activities | 194,065 | -1,039,570 | -93,841 |
| Net cash inflow (outflow) from financing activities | -4,440 | 942,107 | 352,966 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 2 | 11 | 1 |
| Increase (decrease) in cash and cash equivalents in the current period | 96,313 | -224,616 | 301,547 |
| Beginning balance of cash and cash equivalents | 749,443 | 974,059 | 672,512 |
| Ending balance of cash and cash equivalents | 845,756 | 749,443 | 974,059 |
| 項目 | 2025 | 2024 | 2023 |
|---|---|---|---|
| Current asset | 1,535,315 | 1,681,747 | 1,010,106 |
| Non-current asset | 537,914 | 481,855 | 323,537 |
| Total asset | 2,073,229 | 2,163,602 | 1,333,643 |
| Current liability | 123,203 | 116,131 | 77,575 |
| Non-current liability | 104,983 | 109,533 | 118,415 |
| Total liability | 228,186 | 225,664 | 195,990 |
| share capital | 645,432 | 645,432 | 586,020 |
| Equity - secruity token | - | - | - |
| capital reserve | 1,438,884 | 1,438,858 | 531,343 |
| retained earning | -239,292 | -146,369 | 20,284 |
| Other equity | 19 | 17 | 6 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 1,845,043 | 1,937,938 | 1,137,653 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 1,845,043 | 1,937,938 | 1,137,653 |
| Share capital awaiting retirement (unit: share) | 0 | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 14 | 15 | 9 |
